Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - EAGLE PHARMACEUTICALS, INC. | a2218001zs-1a.htm |
| EX-10.3 - EX-10.3 - EAGLE PHARMACEUTICALS, INC. | a2218001zex-10_3.htm |
| EX-10.4 - EX-10.4 - EAGLE PHARMACEUTICALS, INC. | a2218001zex-10_4.htm |
| EX-10.5 - EX-10.5 - EAGLE PHARMACEUTICALS, INC. | a2218001zex-10_5.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Eagle Pharmaceuticals, Inc.
Woodcliff Lake, New Jersey
We hereby consent to the use in the Prospectus constituting a part of this Amendment No. 2 to the Registration Statement of our report dated November 25, 2013, relating to the financial statements of Eagle Pharmaceuticals, Inc., which is contained in that Prospectus. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO USA, LLP
Woodbridge, New Jersey
January 21, 2014